We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Qiagen Licenses Helicase-Dependent Isothermal DNA Amplification System

By Labmedica staff writers
Posted on 08 May 2008
Qiagen (Hamburg, German) and privately held BioHelix Corp. (Beverly, MA, USA) have entered into a non-exclusive worldwide license and supply agreement for BioHelix's Helicase Dependent Amplification (HDA) technology.

HDA is a versatile assay technology to detect and analyze biologic target molecules such as DNA and RNA by amplifying target-specific genetic information with a high level of sensitivity and specificity. Financial terms were not disclosed.

Unlike conventional amplification technologies such as the polymerase chain reaction (PCR), which requires thermocycling, HDA works at a constant temperature, eliminating the need for complex and costly instrumentation. The technology offers a simple reaction workflow and a user-friendly assay design process. Two primers are used to flank the DNA fragment to be amplified, allowing simple and rapid development of new singleplex and/or multiplex assays for use in molecular diagnostics, pharmaceutical development, applied markets, or research.

HDA is compatible with multiple detection technologies including qualitative or quantitative fluorescent detection technologies, as well as with instrumentation designed for use with real-time PCR. The technology is compatible with Qiagen's range of next-generation Hybrid Capture detection platforms, which includes an ultra-high throughput instrument designed for use with assays including Qiagen's human papillomavirus (HPV) assay, Chlamydia trachomatis (CT), and Neisseria gonorrhoeae.

Qiagen uses sample technologies to isolate and process DNA, RNA, and proteins from biologic samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible.

BioHelix specializes in the development of next-generation diagnostic solutions and nucleic acid tests based upon their isothermal HDA platform for infectious diseases, such as methicillin-resistant Staphylococcus aureus (MRSA), Herpes simplex
virus, as well as for genetic diseases.


Related Links:
Qiagen
BioHelix

New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Unit-Dose Packaging solution
HLX
New
C-Reactive Protein Test
mLabs CRP
New
Clostridium Difficile Assay
Revogene C. Difficile

Latest Molecular Diagnostics News

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer